Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Author(s) -
Jordan J. Feld,
Ira M. Jacobson,
Christophe Hézode,
Tarik Asselah,
Peter Ruane,
Norbert H. Gruener,
Armand Abergel,
Alessandra Mangia,
ChingLung Lai,
Henry LikYuen Chan,
Francesco Mazzotta,
Christophe Moreno,
Eric M. Yoshida,
Stephen D. Shafran,
William Towner,
Tram T. Tran,
John McNally,
Anu Osinusi,
Evguenia S. Svarovskaia,
Yanni Zhu,
Diana M. Brainard,
John G. McHutchison,
Kosh Agarwal,
Stefan Zeuzem
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1512610
Subject(s) - medicine , gastroenterology , sofosbuvir , placebo , hepatitis c virus , cirrhosis , genotype , regimen , hepatitis c , immunology , ribavirin , virus , pathology , biology , biochemistry , alternative medicine , gene
A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom